Sleep Apnea Device Receives FDA Approval - Report - MDSpire

Sleep Apnea Device Receives FDA Approval

Randomized trial data support the approval, with sustained improvements in apnea severity observed.

  • By

  • Kathryn Wighton

  • March 19, 2026

  • 2 min

Share

Clinical Report: Sleep Apnea Device Receives FDA Approval

Overview

The aura6000 System, a hypoglossal nerve stimulation therapy, has received FDA approval for adult patients with moderate to severe obstructive sleep apnea who are intolerant to first-line therapies. The device demonstrated significant reductions in apnea-hypopnea index and improved oxygen desaturation index in clinical trials.

Background

Obstructive sleep apnea (OSA) is a prevalent condition that can lead to serious health complications if untreated. Traditional therapies, such as positive airway pressure (PAP), are not suitable for all patients, highlighting the need for alternative treatment options. The approval of the aura6000 System represents a significant advancement in the management of OSA, particularly for patients who have failed or are ineligible for conventional therapies.

Data Highlights

OutcomeBaseline7 Months13 Months
Median Apnea-Hypopnea Index34.3 events/hour11.6 events/hour11.0 events/hour
Responder RateN/A65%N/A
Oxygen Desaturation Index ImprovementN/A69%N/A

Key Findings

  • The aura6000 System is the first hypoglossal nerve stimulation device approved in the US without contraindications related to complete concentric collapse.
  • 65% of patients in the OSPREY trial met responder criteria at 12 months.
  • Median apnea-hypopnea index decreased from 34.3 to 11.0 events per hour over 13 months.
  • 69% of treated patients achieved at least a 25% reduction in oxygen desaturation index at 7 months.
  • The device does not require drug-induced sleep endoscopy prior to implantation.

Clinical Implications

The aura6000 System offers a new treatment option for patients with moderate to severe OSA who are intolerant to or have failed first-line therapies. Clinicians should consider this device for eligible patients, particularly those with a higher risk of complete concentric collapse, as it expands treatment options without the need for invasive pre-implantation procedures.

Conclusion

The FDA approval of the aura6000 System marks a significant advancement in the treatment landscape for obstructive sleep apnea, providing a viable alternative for patients who cannot tolerate traditional therapies.

References

  1. LivaNova PLC, Press Release, 2023 -- Sleep Apnea Device Receives FDA Approval
  2. ADA News, 2023 -- Code Maintenance Committee approves four new CDT codes for sleep apnea
  3. ADA News, 2026 -- January JADA outlines emerging dental therapies for obstructive sleep apnea
  4. Clinical Research in Cardiology, 2020 -- Use of Automatic Positive Airway Pressure in Managing Obstructive Sleep Apnea Among Patients with Heart Failure and Reduced Ejection Fraction
  5. Referral of adults with obstructive sleep apnea for surgical consultation: an American Academy of Sleep Medicine clinical practice guideline - PMC
  6. atlantic health system — Beyond CPAP: Hypoglossal Nerve Stimulation Transforms OSA Management at Morristown Medical Center
  7. Beyond CPAP: Hypoglossal Nerve Stimulation Transforms OSA Management at Morristown Medical Center
  8. 2025 VA/DoD Clinical Practice Guideline for OSA
  9. Referral of adults with obstructive sleep apnea for surgical consultation: an American Academy of Sleep Medicine clinical practice guideline - PMC
  10. The new engl and jour nal of medicine

Original Source(s)

Sleep Apnea Device Receives FDA Approval

  • by Kathryn Wighton

  • March 19, 2026

Related Content

Retatrutide Shows 28% Weight Loss in Phase 3 Trial

Nearly half of participants receiving the highest dose achieved at least 30% body weight reduction.

Invasive NSTEMI Strategy Shows No Benefit in Frail Patients

Frailty severity may identify older patients least likely to benefit—and potentially at higher risk—with invasive management.

AI Scribes Lag Clinicians on Note Quality

A VHA study across 11 vendors finds AI-generated primary care notes score lower than clinician-written notes, with the largest deficits in thoroughness, organization, and usefulness